Granules India completes acquisition of Senn Chemicals
Strengthening capabilities in Peptide Therapeutics and CDMO services
Strengthening capabilities in Peptide Therapeutics and CDMO services
The acquisition aligns with Granules' vision to enter the rapidly expanding peptide-based anti-diabetic and anti-obesity market
Novel illumination system with key components molded in Radel® PPSU for durability and repeated sterilization
This acquisition positions Suven as a key player in one of the fastest growing segments of the Pharma CDMO landscape
These clinical studies support the interchangeability of adalimumab-fkjp at low-concentration with high-concentration adalimumab and ustekinumab biosimilarity
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Late-breaker Phase 3 STRIDE-10 trial presented as an oral presentation at European Society of Clinical Microbiology and Infectious Diseases
The acquisition of Healint aligns with Aptar Digital Health’s strategy to broaden its portfolio in neurology and strengthen its global footprint for digital health deployment
The commissioning of the facility represents the culmination of a £45m investment to address rapidly growing demand for ADC manufacturing, supported by a £2.4m Scottish Enterprise grant
Subscribe To Our Newsletter & Stay Updated